914610-39-2

Basic information

• Product Name: 4-(4-Methylpiperazin-1-ylsulfonyl)phenylboronic acid pinacol ester
• Synonyms: 4-(4-Methylpiperazin-1-ylsulfonyl)phenylboronic acid pinacol ester;4-(4-Methylhomopiperazin-1-ylsulfonyl)phenylboronic acid pinacol ester;1-Methyl-4-[4-(4,4,5,5-tetraMethyl-[1,3,2]dioxaborolan-2-yl)-benzenesulfonyl]-piperazine;1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylsulfonyl)piperazine;1-Methyl-4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonyl]piperazine
• CAS NO: 914610-39-2
• Molecular Formula: C₁₇H₂₇BN₂O₄S
• Molecular Weight: 384
• Mol File: 914610-39-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-(4-Methylpiperazin-1-ylsulfonyl)phenylboronic acid pinacol ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Methylpiperazin-1-ylsulfonyl)phenylboronic acid pinacol ester(914610-39-2)
• EPA Substance Registry System: 4-(4-Methylpiperazin-1-ylsulfonyl)phenylboronic acid pinacol ester(914610-39-2)

Safety Data

• Hazardous Substances Data: 914610-39-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
4-(4-Methylpiperazin-1-ylsulfonyl)phenylboronic acid pinacol ester is used as a building block in organic synthesis for the development of new pharmaceuticals. Its unique structure allows for the creation of a wide range of biologically active compounds, making it a valuable asset in drug discovery and development.
Used in Medicinal Chemistry Research:
4-(4-Methylpiperazin-1-ylsulfonyl)phenylboronic acid pinacol ester is used as a protease inhibitor in medicinal chemistry research. Its potential to inhibit proteases makes it an important chemical for studying enzyme function and developing new therapeutic agents.
Used in Chemical Industry:
4-(4-Methylpiperazin-1-ylsulfonyl)phenylboronic acid pinacol ester holds significant value in the chemical industry due to its versatile properties. Its ability to form a wide range of biologically active compounds makes it a valuable reagent for various chemical processes and applications.

Upstream product

• 837-12-7 1-((4-bromophenyl)sulfonyl)-4-methylpiperazine 
• 73183-34-3 bis(pinacol)diborane 
• 98-58-8 4-bromobenzenesulfonyl chloride 
• 109-01-3 1-methyl-piperazine 

Downstream Products

• 1254319-49-7 (S)-tert-butyl 4-(1-amino-3-(4'-(4-methylpiperazin-1-ylsulfonyl)biphenyl-4-yl)-1-oxopropan-2-ylcarbamoyl)tetrahydro-2H-pyran-4-ylcarbamate 
• 1464150-75-1 4-(6-(4-(4-methylpiperazin-1-ylsulfonyl)phenyl)imidazo[1,2-a]pyrazin-3-yl)benzonitrile 

Relevant articles and documents

Illuminating a Dark Kinase: Structure-Guided Design, Synthesis, and Evaluation of a Potent Nek1 Inhibitor and Its Effects on the Embryonic Zebrafish Pronephros

NIMA-related kinase 1 (Nek1) has lately garnered attention for its widespread function in ciliogenesis, apoptosis, and the DNA-damage response. Despite its involvement in various diseases and its potential as a cancer drug target, no directed medicinal chemistry efforts toward inhibitors against this dark kinase are published. Here, we report the structure-guided design of a potent small-molecule Nek1 inhibitor, starting from a scaffold identified by kinase cross-screening analysis. Seven lead compounds were identified in silico and evaluated for their inhibitory activity. The top compound, 10f, was further profiled for efficacy, toxicity, and bioavailability in a zebrafish polycystic kidney disease model. Administration of 10f caused the expansion of fluorescence-labeled proximal convoluted tubules, supporting our hypothesis that Nek1-inhibition causes cystic kidneys in zebrafish embryos. Compound 10f displayed insignificant inhibition in 48 of 50 kinases in a selectivity test panel. The findings provide a powerful tool to further elucidate the function and pharmacology of this neglected kinase.

Efficient Synthesis of New 2H-Chromene Retinoids Hybrid Derivatives by Suzuki Cross-coupling Reactions

In an attempt to improve anticancer activity, a series of retinoids–chromene hybrids was described. The novel heterocyclic chromene–retinoids hybrid including oxygen as a heteroatom in a six-membered cyclic ring (2H-chromene or 2H-1-benzopyran) was design

Structure-based design and in vivo anti-arthritic activity evaluation of a potent dipeptidyl cyclopropyl nitrile inhibitor of cathepsin C

Cathepsin C (CatC)is a dipeptidyl-exopeptidase which activates neutrophil serine protease precursors (elastase, proteinase 3, cathepsin G and NSP4)by removing their N-terminal propeptide in bone marrow cells at the promyelocytic stage of neutrophil differ

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery

Tropical protozoal infections are a significant cause of morbidity and mortality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estimated combined burden of over 87 million disability-adjusted life years. New drugs are needed for each of these diseases. Building on the previous identification of NEU-617 (1) as a potent and nontoxic inhibitor of proliferation for the HAT pathogen (Trypanosoma brucei), we have now tested this class of analogs against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria). Based on hits identified in this screening campaign, we describe the preparation of several replacements for the quinazoline scaffold and report these inhibitors' biological activities against these parasites. In doing this, we have identified several potent proliferation inhibitors for each pathogen, such as 4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)quinoline-3-carbonitrile (NEU-924, 83) for T. cruzi and N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)cinnolin-4-amine (NEU-1017, 68) for L. major and P. falciparum.

Kinase scaffold repurposing for neglected disease drug discovery: Discovery of an efficacious, lapatanib-derived lead compound for trypanosomiasis

Human African trypanosomiasis (HAT) is a neglected tropical disease caused by the protozoan parasite Trypanosoma brucei. Because drugs in use against HAT are toxic and require intravenous dosing, new drugs are needed. Initiating lead discovery campaigns b

PEPTIDASE INHIBITORS

Novel compounds of the formula (I) wherein R1, R2, D, A, B and X have the meanings defined herein, pharmaceutical compositions comprising them as active ingredient, as well as their use in medicine, in particular as peptidase inhibitors, more specifically

AURORA KINASE INHIBITORS

Disclosed herein are Aurora kinase Inhibitors represented by Structural Formula (I): Values for the variables in Structural Formula (I) are defined herein.

IMIDAZOLYL-SUBSTITUTED DIAZABENZOPHENONE COMPOUNDS

The compounds of formula (I) in which X, Y, R1 and R2 have the meanings as given in the description are novel effective inhibitors of the inducible nitric oxide synthase.

IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS

The compounds of formula (I) in which R1, R2, R3, R4, R5 and A have the meanings as given in the description are novel effective iNOS inhibitors.